Stocktoria
Solid Biosciences Inc. SLDB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-01-26
Chart by TradingView
1/9
Piotroski F — financial health
-10.16
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $8.1M | $13.6M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Shareholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M |
| Ratios | |||||
| Operating margin | — | — | — | -1315.2% | -530.5% |
| FCF margin | — | — | — | -1247.7% | -580.4% |
| Current ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 |
| Revenue growth | — | — | — | -40.6% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 2,050,843 | $14.8M |
| RENAISSANCE TECHNOLOGIES LLC | 124,272 | $894,758 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.16 (distress)
- Working capital / assets 0.74
- Retained earnings / assets -4.119
- EBIT / assets -0.771
- Equity / liabilities 3.427
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001707502 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.